The Value of Tucatinib in Metastatic HER2-Positive Breast Cancer Patients: An Italian Cost-Effectiveness Analysis
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The Value of Tucatinib in Metastatic HER2-Positive Breast Cancer Patients: An Italian Cost-Effectiveness Analysis
Authors
Keywords
-
Journal
Cancers
Volume 15, Issue 4, Pages 1175
Publisher
MDPI AG
Online
2023-02-13
DOI
10.3390/cancers15041175
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cost-effectiveness Analysis of Tisagenlecleucel Versus Blinatumomab in Children and Young Adults with Acute Lymphoblastic Leukemia: Partitioned Survival Model to Assess the Impact of an Outcome-Based Payment Arrangement
- (2022) Amy Gye et al. PHARMACOECONOMICS
- Role of Economic Evaluations on Pricing of Medicines Reimbursed by the Italian National Health Service
- (2022) Pierluigi Russo et al. PHARMACOECONOMICS
- Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2021) Hyuna Sung et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Evaluation of Tucatinib in HER2-Positive Breast Cancer Patients With Brain Metastases: A United States-Based Cost-Effectiveness Analysis
- (2021) Liangliang Dong et al. Clinical Breast Cancer
- Efficacy of tucatinib for HER2-positive metastatic breast cancer after HER2-targeted therapy: a network meta-analysis
- (2021) Kendra DeBusk et al. Future Oncology
- ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
- (2021) A. Gennari et al. ANNALS OF ONCOLOGY
- Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis
- (2021) G. Curigliano et al. ANNALS OF ONCOLOGY
- Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial
- (2020) Cristina Saura et al. JOURNAL OF CLINICAL ONCOLOGY
- Lifestyle Intervention on Body Weight and Physical Activity in Patients with Breast Cancer Can Reduce the Risk of Death in Obese Women: The EMILI Study
- (2020) Laura Cortesi et al. Cancers
- Cost-Effectiveness of Tucatinib in Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer From the US and Chinese Perspectives
- (2020) Qiuji Wu et al. Frontiers in Oncology
- Systemic therapy for metastatic HER2-positive breast cancer
- (2020) Philip Bredin et al. SEMINARS IN ONCOLOGY
- Cost-effectiveness analysis of utidelone plus capecitabine for metastatic breast cancer in China
- (2019) Mengting Liao et al. JOURNAL OF MEDICAL ECONOMICS
- Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
- (2019) Rashmi K. Murthy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Controversies in monitoring metastatic breast cancer during systemic treatment. Results of a GIM (Gruppo Italiano Mammella) survey
- (2018) Marta Bonotto et al. BREAST
- Randomized Phase III Trial of Trastuzumab Plus Capecitabine With or Without Pertuzumab in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Who Experienced Disease Progression During or After Trastuzumab-Based Therapy
- (2017) Ander Urruticoechea et al. JOURNAL OF CLINICAL ONCOLOGY
- The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer
- (2016) Jennifer L. Hsu et al. CANCER AND METASTASIS REVIEWS
- Cost-Effectiveness Analysis of Regorafenib for Metastatic Colorectal Cancer
- (2015) Daniel A. Goldstein et al. JOURNAL OF CLINICAL ONCOLOGY
- The Role of Half-Cycle Correction in the Models Used for Health Technology Assessment
- (2013) B. Nemeth et al. VALUE IN HEALTH
- Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves
- (2012) Patricia Guyot et al. BMC Medical Research Methodology
- Model Parameter Estimation and Uncertainty Analysis
- (2012) Andrew H. Briggs et al. MEDICAL DECISION MAKING
- Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
- (2012) Sunil Verma et al. NEW ENGLAND JOURNAL OF MEDICINE
- Population-based Estimate of the Prevalence of HER-2 Positive Breast Cancer Tumors for Early Stage Patients in the US
- (2010) Kathleen A. Cronin et al. CANCER INVESTIGATION
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started